Targeted treatment of cancer with monoclonal antibodies increases the benefit for patients. In order to improve the anti-tumor activity of monoclonal antibodies, multi-specific antibodies have entered the research fie...Targeted treatment of cancer with monoclonal antibodies increases the benefit for patients. In order to improve the anti-tumor activity of monoclonal antibodies, multi-specific antibodies have entered the research field. The emergence of various techniques to produce multi-specific recombinant antibody molecules has led to the selection of target combinations in various forms. To date, only a few multi-specific constructs have entered phase III clinical trials, in contrast to classical monoclonal antibodies. Some of the format options are outlined from a technical point of view. We focus on the achievements and prospects of the underlying technologies for generating biand multispecific antibodies.展开更多
Monoclonal antibodies(mAbs) have become a major class of therapeutic agents providing effective alternatives to treating various human diseases.To date,15 mAbs have been approved by regulatory agencies in the world fo...Monoclonal antibodies(mAbs) have become a major class of therapeutic agents providing effective alternatives to treating various human diseases.To date,15 mAbs have been approved by regulatory agencies in the world for clinical use in oncology indications.The selectivity and specificity,the unique pharmacokinetics,and the ability to engage and activate the host immune system differentiate these biologics from traditional small molecule anticancer drugs.mAb-based regimens have brought clinical benefits,including improvements in overall survival,to patients with a variety of cancers.Many challenges still remain,however,to fully realize the potential of these new medicines.With our further understanding of cancer biology,mechanism of antibody action,and advancement of antibody engineering technologies,many novel antibody formats or antibody-derived molecules are emerging as promising new generation therapeutics.Carefully designed and engineered,they retain the advantage of specificity and selectivity of original antibodies,but in the meantime acquire additional special features such as improved pharmacokinetics,increased selectivity,and enhanced anticancer efficacy.Promising clinical results are being generated with these newly improved antibody-based therapeutics.展开更多
A cDNA library was constructed in λgt11 vectors, complementary to the mRNA isolated from a mouse hybridoma raised against potato virus Y(PVY). Thirty cDNA clones were selected from the cDNA library by in situ immunoh...A cDNA library was constructed in λgt11 vectors, complementary to the mRNA isolated from a mouse hybridoma raised against potato virus Y(PVY). Thirty cDNA clones were selected from the cDNA library by in situ immunohybridization with goat anti-mouse kappa-chain-specific antibody conjugated to alkaline phosphatase, from which one clone, k6, having the largest insert was characterized by sequence analysis. The result shows that the immunoglobulin messenger RNA corresponding to k6 is 956 nucleotides in length excluding the poly(A) region, among which 31 bases code for the 5’ non-coding region, 57 for the leader sequence of the protein, 657 for the mature protein and 211 for the 3’ non-coding region. Comparison of deduced amino acid sequences of the protein and other kappa light chains shows that they share a 100% identity in their constant regions(CL) and 93.7% identity in their variable regions(VL). The kappa light chain encoded by k6 is considered to be specific to PVY since only one type of light chain is expressed in the hybridoma.展开更多
文摘Targeted treatment of cancer with monoclonal antibodies increases the benefit for patients. In order to improve the anti-tumor activity of monoclonal antibodies, multi-specific antibodies have entered the research field. The emergence of various techniques to produce multi-specific recombinant antibody molecules has led to the selection of target combinations in various forms. To date, only a few multi-specific constructs have entered phase III clinical trials, in contrast to classical monoclonal antibodies. Some of the format options are outlined from a technical point of view. We focus on the achievements and prospects of the underlying technologies for generating biand multispecific antibodies.
文摘Monoclonal antibodies(mAbs) have become a major class of therapeutic agents providing effective alternatives to treating various human diseases.To date,15 mAbs have been approved by regulatory agencies in the world for clinical use in oncology indications.The selectivity and specificity,the unique pharmacokinetics,and the ability to engage and activate the host immune system differentiate these biologics from traditional small molecule anticancer drugs.mAb-based regimens have brought clinical benefits,including improvements in overall survival,to patients with a variety of cancers.Many challenges still remain,however,to fully realize the potential of these new medicines.With our further understanding of cancer biology,mechanism of antibody action,and advancement of antibody engineering technologies,many novel antibody formats or antibody-derived molecules are emerging as promising new generation therapeutics.Carefully designed and engineered,they retain the advantage of specificity and selectivity of original antibodies,but in the meantime acquire additional special features such as improved pharmacokinetics,increased selectivity,and enhanced anticancer efficacy.Promising clinical results are being generated with these newly improved antibody-based therapeutics.
文摘A cDNA library was constructed in λgt11 vectors, complementary to the mRNA isolated from a mouse hybridoma raised against potato virus Y(PVY). Thirty cDNA clones were selected from the cDNA library by in situ immunohybridization with goat anti-mouse kappa-chain-specific antibody conjugated to alkaline phosphatase, from which one clone, k6, having the largest insert was characterized by sequence analysis. The result shows that the immunoglobulin messenger RNA corresponding to k6 is 956 nucleotides in length excluding the poly(A) region, among which 31 bases code for the 5’ non-coding region, 57 for the leader sequence of the protein, 657 for the mature protein and 211 for the 3’ non-coding region. Comparison of deduced amino acid sequences of the protein and other kappa light chains shows that they share a 100% identity in their constant regions(CL) and 93.7% identity in their variable regions(VL). The kappa light chain encoded by k6 is considered to be specific to PVY since only one type of light chain is expressed in the hybridoma.
